The Promise and Challenges of Implementing Pharmacogenomics to Improve Population Health: Where Are we Heading with Preemptive Pharmacogenomic Screening?
Individual variability in drug response efficacy or safety is becoming an increasing problem globally, given the growing population of older adults. Reasons for this variability include genomic factors, an area of study called pharmacogenomics. With genotyping technologies now widely available and decreasing in cost, implementing pharmacogenomics into clinical practice is widely viewed as an initial step in mainstreaming genomic medicine. The benefits of pharmacogenomic testing before starting drug therapy has been well documented for several single gene-drug combinations. In addition, the clinical utility of a pre-emptive genotyping strategy using a pharmacogenetic panel is being rigorously assessed. However, major challenges of implementation lie at the point of integration into healthcare systems, including the modification of clinical pathways and a large knowledge gap in pharmacogenomics in the healthcare workforce. Pharmacogenomics can also be used in a broader sense for drug discovery and development, with increasing evidence suggesting that genomically defined targets have an increased success rate during clinical development. Our speaker will review recent developments in the field of pharmacogenomics and the ongoing challenges in equitable translation of discoveries into clinical practice and public health programs.
Professor Sir Munir Pirmohamed, MB ChB (Hons), PhD, FRCP, FRCP(E), FFPM, FRSB, FBPhS, FMedSci
David Weatherall Chair of Medicine and National Health Service Chair of Pharmacogenetics
Director, Centre for Drug Safety Science and Wolfson Centre for Personalised Medicine
Institute of Systems, Molecular and Integrative Biology (ISMIB)
University of Liverpool,
- A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.
Swen JJ, et al. Lancet. 2023 Feb 4;401(10374):347-356.
- Pharmacogenomics: current status and future perspectives.
Pirmohamed M. Nat Rev Genet. 2023 Jan 27.
- Drug-Drug-Gene Interactions in Cardiovascular Medicine.
Asiimwe IG, et al. Pharmgenomics Pers Med. 2022 Nov 2;15:879-911
- HLA Allele-Restricted Immune-Mediated Adverse Drug Reactions: Framework for Genetic Prediction.
Jaruthamsophon K, et al. Annu Rev Pharmacol Toxicol, 2022 Jan 6;62:509-529.
- Pharmacogenomics decision support in the U-PGx project: Results and advice from clinical implementation across seven European countries. Blagec K, et al. PLoS One. 2022 Jun 8;17(6):e0268534.
- Psychiatry pharmacogenomics: Africans are not at the table.
Frances Adiukwu et al. The Lancet Psychiatry 2023 1 (2) 80
- Sequencing of genes of drug response in tumor DNA and implications for precision medicine in cancer patients. Nancy Gillis et al. The Pharmacogenomics Journal 2023 1
- Clinical utility of pharmacogenetics in a psychiatric and primary care population
KN Bohlen et al, The PGX Journal, October 27, 2022
- Nine-gene pharmacogenomics profile service: The Mayo Clinic experience.
Matey Eric T et al. The Pharmacogenomics Journal 2022 10 (1) 69-74
- A Systematic Review of Polygenic Models for Predicting Drug Outcomes
A Siemens et al, J Per Med, August 29, 2022
- Office of Genomics and Precision Public Health
- Precision Public Health Network, University of North Carolina at Chapel Hill